According to Prelude Therapeutics's latest financial reports the company's current EPS (TTM) is -2,06ย โฌ. In 2022 the company made an earnings per share (EPS) of -2,32ย โฌ a decrease over its 2021 EPS that were of -2,30ย โฌ.